Equities

Larimar Therapeutics Inc

Larimar Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.04
  • Today's Change-0.25 / -2.69%
  • Shares traded581.90k
  • 1 Year change+268.98%
  • Beta0.9595
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

  • Revenue in USD (TTM)0.00
  • Net income in USD-64.77m
  • Incorporated2005
  • Employees42.00
  • Location
    Larimar Therapeutics IncTHREE BALA PLAZA EAST. SUITE 506BALA CYNWYD 19004United StatesUSA
  • Phone+1 (617) 622-4003
  • Fax+1 (302) 655-5049
  • Websitehttps://larimartx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Q32 Bio Inc0.00-49.66m548.25m42.00--29.86-----7.44-7.440.001.510.00----0.00-27.86-34.98-33.25-37.92-------971.76----0.4079---63.97-26.32-2,156.96---60.90--
Arcturus Therapeutics Holdings Inc160.40m-62.64m550.85m180.00--2.11--3.43-2.33-2.335.959.670.3873--4.69891,105.60-15.13-19.66-18.67-24.90-----39.05-77.55----0.00---19.0360.31-417.95--14.44--
Aura Biosciences Inc0.00-80.69m552.61m88.00--2.89-----1.79-1.790.003.860.00----0.00-39.26---41.21--------------0.00-------30.03------
Sangamo Therapeutics Inc12.28m-249.68m562.20m405.00--23.73--45.79-1.38-1.380.06640.11380.0587--7.4530,313.58-119.44-26.09-153.51-31.04-----2,033.68-136.53----0.00--58.3415.85-34.09---13.25--
Regenxbio Inc84.33m-238.81m572.74m344.00--1.90--6.79-5.03-5.031.766.090.1463--3.27245,136.60-41.43-16.75-51.75-19.0854.3678.27-283.19-72.06----0.00---19.94-16.216.00---5.59--
Celcuity Inc0.00-82.59m581.37m55.00--3.29-----2.74-2.740.004.770.00----0.00-37.03-37.32-39.38-39.16------------0.3525-------57.99---31.12--
Larimar Therapeutics Inc0.00-64.77m592.76m42.00--2.99-----1.15-1.150.003.110.00----0.00-40.11-42.22-43.16-47.14------------0.00-------4.51--8.71--
Alector Inc61.51m-158.41m593.47m241.00--4.99--9.65-1.71-1.710.66071.210.1035----252,082.00-26.66-20.00-35.58-23.81-----257.54-124.07----0.00---27.3628.522.19--4.79--
SS Innovations International Inc14.41m-23.68m597.59m239.00--35.19--41.47-0.1396-0.13960.08470.09950.60032.285.0860,293.01-98.66-161.38-216.15-449.7628.42-79.79-164.35-495.770.9128-45.390.4172-------846.31--159.31--
Corvus Pharmaceuticals Inc0.00-22.62m597.99m28.00--11.67-----0.4458-0.44580.000.81890.00----0.00-36.89-38.31-44.60-43.34-----------22.180.00------34.57---37.45--
ACELYRIN Inc0.00-299.80m604.84m130.00--1.06-----3.06-3.060.005.710.00----0.00-40.33---43.71--------------0.00-------489.21------
Monte Rosa Therapeutics Inc14.98m-119.39m614.34m103.00--2.99--41.02-1.83-1.830.22153.350.0528--33.69112,594.00-42.10---47.48-------797.26------0.00-------24.75------
ProKidney Corp0.00-38.68m622.80m163.00---------0.5905-0.59050.00-7.730.00----0.00-27.97------------------0.0003------67.17------
Terns Pharmaceuticals Inc0.00-95.90m629.62m66.00--2.40-----1.31-1.310.003.110.00----0.00-36.84-41.34-38.72-45.70-------31,010.30----0.00-------49.49---26.60--
Third Harmonic Bio Inc0.00-39.20m632.90m51.00--2.34-----0.9694-0.96940.006.590.00----0.00-13.36---13.66--------------0.00------12.32------
Data as of Nov 12 2024. Currency figures normalised to Larimar Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

42.21%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 30 Jun 20246.05m9.47%
Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 20244.49m7.04%
Janus Henderson Investors US LLCas of 30 Jun 20244.38m6.86%
BlackRock Fund Advisorsas of 30 Jun 20242.91m4.55%
The Vanguard Group, Inc.as of 30 Jun 20242.45m3.84%
Verition Fund Management LLCas of 30 Jun 20241.59m2.50%
Adage Capital Management LPas of 30 Jun 20241.37m2.15%
Driehaus Capital Management LLCas of 30 Jun 20241.31m2.06%
Woodline Partners LPas of 30 Jun 20241.24m1.95%
Geode Capital Management LLCas of 30 Jun 20241.14m1.79%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.